EA201791669A3 - Новые терапевтические подходы в лечении смт и связанных с ней расстройств - Google Patents

Новые терапевтические подходы в лечении смт и связанных с ней расстройств

Info

Publication number
EA201791669A3
EA201791669A3 EA201791669A EA201791669A EA201791669A3 EA 201791669 A3 EA201791669 A3 EA 201791669A3 EA 201791669 A EA201791669 A EA 201791669A EA 201791669 A EA201791669 A EA 201791669A EA 201791669 A3 EA201791669 A3 EA 201791669A3
Authority
EA
Eurasian Patent Office
Prior art keywords
related disorders
smt
treatment
new therapeutic
therapeutic approaches
Prior art date
Application number
EA201791669A
Other languages
English (en)
Other versions
EA035711B1 (ru
EA201791669A2 (ru
Inventor
Даниель Коэн
Илья Чумаков
Оксана Герасименко
Сергей Набирошкин
Original Assignee
Фарнекст
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фарнекст filed Critical Фарнекст
Publication of EA201791669A2 publication Critical patent/EA201791669A2/ru
Publication of EA201791669A3 publication Critical patent/EA201791669A3/ru
Publication of EA035711B1 publication Critical patent/EA035711B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к композициям и способам для лечения болезни Шарко-Мари-Тусса и связанных с ней расстройств. Более конкретно, изобретение относится к комбинированной терапии для лечения указанного заболевания, воздействуя на экспрессию РМР22 у больного.
EA201791669A 2007-11-30 2008-11-28 Применение d-сорбита для лечения смт и связанных с ним расстройств EA035711B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07301614A EP2065038A1 (en) 2007-11-30 2007-11-30 New therapeutic approaches for treating Charcot-Marie-Tooth disease
US99180007P 2007-12-03 2007-12-03

Publications (3)

Publication Number Publication Date
EA201791669A2 EA201791669A2 (ru) 2017-12-29
EA201791669A3 true EA201791669A3 (ru) 2018-03-30
EA035711B1 EA035711B1 (ru) 2020-07-29

Family

ID=39264515

Family Applications (3)

Application Number Title Priority Date Filing Date
EA201000914A EA019402B1 (ru) 2007-11-30 2008-11-28 Композиции и способ лечения болезни шарко-мари-тусса
EA201791669A EA035711B1 (ru) 2007-11-30 2008-11-28 Применение d-сорбита для лечения смт и связанных с ним расстройств
EA201301078A EA032767B1 (ru) 2007-11-30 2008-11-28 Применение баклофена или его соли для лечения болезни шарко-мари-тусса (смт) и связанного с ней расстройства

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201000914A EA019402B1 (ru) 2007-11-30 2008-11-28 Композиции и способ лечения болезни шарко-мари-тусса

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201301078A EA032767B1 (ru) 2007-11-30 2008-11-28 Применение баклофена или его соли для лечения болезни шарко-мари-тусса (смт) и связанного с ней расстройства

Country Status (24)

Country Link
US (6) US8992891B2 (ru)
EP (4) EP2065038A1 (ru)
JP (4) JP5953000B2 (ru)
KR (1) KR101546031B1 (ru)
CN (2) CN101883561B (ru)
AU (1) AU2008328745B2 (ru)
BR (1) BRPI0819678A2 (ru)
CA (3) CA3031490C (ru)
CY (2) CY1113980T1 (ru)
DK (2) DK2211846T3 (ru)
EA (3) EA019402B1 (ru)
ES (3) ES2831855T3 (ru)
HR (2) HRP20130345T1 (ru)
HU (1) HUE040596T2 (ru)
IL (1) IL205741A0 (ru)
LT (1) LT2609916T (ru)
MX (1) MX2010005709A (ru)
NZ (1) NZ585440A (ru)
PL (2) PL2211846T3 (ru)
PT (2) PT2211846E (ru)
SI (2) SI2609916T1 (ru)
TR (1) TR201819564T4 (ru)
WO (1) WO2009068668A1 (ru)
ZA (1) ZA201003610B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) * 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US20110213193A1 (en) * 2008-08-28 2011-09-01 The Florida International University Board Of Trustees Magnetic Nanodelivery of Therapeutic Agents Across the Blood Brain Barrier
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9494605B2 (en) * 2009-11-20 2016-11-15 Pharnext Diagnostic tools for charcot-marie-tooth disease
EP2523661B1 (en) 2010-01-15 2017-05-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Nkcc inhibitors for the treatment of autism
EP2624832B1 (en) * 2010-10-08 2017-09-27 Vib Vzw Hdac inhibitors to treat charcot-marie-tooth disease
CN102464610B (zh) * 2010-11-16 2014-07-30 北大方正集团有限公司 一种美替拉酮的制备方法
EP3502236B1 (en) 2011-02-18 2023-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
AU2012221704B2 (en) 2011-02-23 2013-12-05 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
CN102247324B (zh) * 2011-07-14 2012-11-21 海南美兰史克制药有限公司 一种氟马西尼脂质体注射液
CN102887830B (zh) * 2012-09-04 2013-11-27 苏州弘森药业有限公司 一种盐酸酚苄明的制备方法
WO2014063163A1 (en) 2012-10-19 2014-04-24 Block Jonathan D Systems and methods for nerve mapping and monitoring
EP2931267A1 (en) * 2012-12-17 2015-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of x-linked charcot-marie-tooth
WO2014195394A1 (en) 2013-06-05 2014-12-11 Pharnext Stable oral solutions for combined api
WO2015121218A1 (en) 2014-02-11 2015-08-20 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
SG11201606485VA (en) * 2014-02-24 2016-09-29 Pharnext New compositions for treating mechanical neuronal injuries
WO2016187595A2 (en) * 2015-05-20 2016-11-24 Lupin Atlantis Holdings Sa Oral pharmaceutical composition of methylergonovine
AU2017229778A1 (en) 2016-03-09 2018-08-16 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting PMP22 expression
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
WO2018014007A1 (en) * 2016-07-14 2018-01-18 Sidewaystrategies Llc System and methods for improving diagnostic evoked potential studies for functional assessments of nerves and nerve pathways
CA3044691A1 (en) 2016-10-26 2018-05-03 Genea Biocells USA (Holdings), Inc. Improved generation of muscle lineage cells and therapeutic uses thereof
BR112020001755A2 (pt) 2017-07-28 2020-07-21 Applied Therapeutics Inc. composições e métodos para o tratamento de galactosemia
EP3966320A4 (en) * 2019-05-07 2023-10-25 University of Miami TREATMENT AND DETECTION OF HEREDITARY NEUROPATHIES AND ASSOCIATED DISORDERS
AU2021264454A1 (en) * 2020-05-01 2022-12-08 Applied Therapeutics, Inc. Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency
EP4019016A1 (en) * 2020-12-24 2022-06-29 Allaysis, LLC Methods of administering intravenous baclofen
US11523984B1 (en) * 2021-11-12 2022-12-13 Amneal Pharmaceuticals Llc Compositions and methods of administering baclofen
WO2023182288A1 (ja) * 2022-03-22 2023-09-28 国立大学法人京都大学 シャルコー・マリー・ツース病の治療または予防薬

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427904B (en) 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
JP4346817B2 (ja) 1997-09-30 2009-10-21 第一三共ヘルスケア株式会社 経口投与製剤
WO2000017358A2 (en) * 1998-09-22 2000-03-30 Incyte Genomics, Inc. Human chaperone proteins
EP1117425A2 (en) * 1998-10-02 2001-07-25 Celtrix Pharmaceuticals, Inc. Methods for the treatment of non-thyroid disorders
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
WO2002049607A2 (en) 2000-12-20 2002-06-27 Firmenich Sa Flavoured oral drug delivery system
JP3805646B2 (ja) 2001-05-25 2006-08-02 久光メディカル株式会社 医薬液剤
ES2398348T3 (es) * 2001-07-04 2013-03-15 Sun Pharma Advanced Research Company Ltd Sistema de administración de fármacos controlada por retención gástrica
CA2478558C (en) * 2002-03-14 2012-09-11 Euro-Celtique, S.A. Naltrexone hydrochloride compositions
WO2003082204A2 (en) * 2002-03-26 2003-10-09 Euro-Celtique S.A. Sustained-release gel coated compositions
FR2842422B1 (fr) 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
JP2004049093A (ja) * 2002-07-18 2004-02-19 Meiji Milk Prod Co Ltd 腸内酪酸上昇食品組成物および医薬品
AU2003258433A1 (en) 2002-08-28 2004-03-19 Merck Frosst Canada Ltd Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
RU2224518C1 (ru) * 2003-02-10 2004-02-27 Дулькис Мария Дмитриевна Жидкая лекарственная форма налтрексона
CN1777411B (zh) * 2003-02-24 2013-01-02 药品生产公司 经粘膜药物递送***
DK2368553T3 (en) * 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
WO2004091593A2 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
WO2004103263A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
ATE464049T1 (de) * 2003-09-25 2010-04-15 Euro Celtique Sa Pharmazeutische kombinationen von hydrocodon und naltrexon
EP1706098A4 (en) 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc MICELLAR SYSTEMS SUITABLE FOR THE DELIVERY OF LIPOPHILIC OR HYDROPHOBIC COMPOUNDS
FR2865648B1 (fr) * 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
US20050220863A1 (en) 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
JP2006131545A (ja) 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
DE102006016990A1 (de) * 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
JP2009536669A (ja) * 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
EP2026813A2 (en) * 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
ES2365574T3 (es) 2007-01-11 2011-10-07 Xenoport, Inc. Formas de dosificación oral para liberación continua de un profármaco de r-baclofeno y procedimientos de tratamiento.
US20080255062A1 (en) 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
US7806721B2 (en) * 2007-08-02 2010-10-05 Tyco Electronics Corporation Patch panel modular jack assembly
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
IT1400067B1 (it) 2010-05-21 2013-05-17 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
EP2727588B1 (en) 2011-03-01 2018-08-29 Pharnext Baclofen and acamprosate based therapy of neurological disorders
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
WO2014195394A1 (en) 2013-06-05 2014-12-11 Pharnext Stable oral solutions for combined api
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease

Also Published As

Publication number Publication date
DK2211846T3 (da) 2013-04-29
US20180250289A1 (en) 2018-09-06
CN104257657B (zh) 2017-07-04
CA2705408C (en) 2019-04-23
US10463640B2 (en) 2019-11-05
EP3459535A1 (en) 2019-03-27
HRP20182147T1 (hr) 2019-03-08
CA3031484A1 (en) 2009-06-04
CA3031490A1 (en) 2009-06-04
PT2211846E (pt) 2013-05-10
CY1113980T1 (el) 2016-07-27
PL2609916T3 (pl) 2019-03-29
EA032767B1 (ru) 2019-07-31
CN101883561A (zh) 2010-11-10
EP2211846A1 (en) 2010-08-04
EA019402B1 (ru) 2014-03-31
BRPI0819678A2 (pt) 2017-05-09
MX2010005709A (es) 2010-11-05
EP3459535B1 (en) 2020-08-12
KR101546031B1 (ko) 2015-08-25
LT2609916T (lt) 2019-02-11
NZ585440A (en) 2011-12-22
US8992891B2 (en) 2015-03-31
DK2609916T3 (en) 2019-01-21
US20200155491A1 (en) 2020-05-21
JP2016145227A (ja) 2016-08-12
US20180360785A1 (en) 2018-12-20
HRP20130345T1 (hr) 2013-07-31
CN101883561B (zh) 2014-07-30
EP2609916A1 (en) 2013-07-03
EP2609916B1 (en) 2018-11-07
JP5953000B2 (ja) 2016-07-13
JP2018109043A (ja) 2018-07-12
AU2008328745A1 (en) 2009-06-04
CY1121183T1 (el) 2020-05-29
EA201000914A1 (ru) 2010-12-30
JP2011504915A (ja) 2011-02-17
CA3031484C (en) 2021-05-04
ES2703508T3 (es) 2019-03-11
PT2609916T (pt) 2019-01-10
AU2008328745B2 (en) 2014-01-30
EA201301078A1 (ru) 2014-06-30
CN104257657A (zh) 2015-01-07
EA035711B1 (ru) 2020-07-29
US10441558B2 (en) 2019-10-15
CA3031490C (en) 2021-05-04
SI2211846T1 (sl) 2013-07-31
JP2019142917A (ja) 2019-08-29
US20100310641A1 (en) 2010-12-09
TR201819564T4 (tr) 2019-01-21
PL2211846T3 (pl) 2013-09-30
SI2609916T1 (sl) 2019-03-29
IL205741A0 (en) 2010-11-30
CA2705408A1 (en) 2009-06-04
ZA201003610B (en) 2011-06-29
EP2065038A1 (en) 2009-06-03
HRP20182147T8 (hr) 2019-04-19
WO2009068668A1 (en) 2009-06-04
KR20100088160A (ko) 2010-08-06
JP6608309B2 (ja) 2019-11-20
EA201791669A2 (ru) 2017-12-29
ES2408785T3 (es) 2013-06-21
EP2211846B1 (en) 2013-02-27
HUE040596T2 (hu) 2019-03-28
US20150157626A1 (en) 2015-06-11
US10322101B2 (en) 2019-06-18
US20180338969A1 (en) 2018-11-29
ES2831855T3 (es) 2021-06-09

Similar Documents

Publication Publication Date Title
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
CY1121134T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συγκολλησης
CY1120807T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συναρμογης σε ενα υποκειμενο
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
EA201200686A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EA201370208A1 (ru) Формы рифаксимина и их применение
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA201300558A1 (ru) Соединения и способы для купирования боли
NO20092637L (no) Fremgangsmater for behandling
EA200901211A1 (ru) Антигены белка с5 и их применение
EA201000365A1 (ru) Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза
EA200970224A1 (ru) Лечение заболеваний хряща
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM